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Abstract
Radiation therapy is an effective cancer treatment modality although tumors
invariably become resistant. Using the transgenic adenocarcinoma of mouse prostate
(TRAMP) model system, we report that a hypofractionated radiation schedule (10
Gy/day for 5 consecutive days) effectively blocks prostate tumor growth in wild type
(β1wt /TRAMP) mice as well as in mice carrying a conditional ablation of β1 integrins in
the prostatic epithelium (β1pc-/- /TRAMP). Since JNK is known to be suppressed by β1
integrins and mediates radiation-induced apoptosis, we tested the effect of SP600125,
an inhibitor of c-Jun amino-terminal kinase (JNK) in the TRAMP model system. Our
results show that SP600125 negates the effect of radiation on tumor growth in β1pc-/- /
TRAMP mice and leads to invasive adenocarcinoma. These effects are associated with
increased focal adhesion kinase (FAK) expression and phosphorylation in prostate
tumors in β1pc-/- /TRAMP mice. In marked contrast, radiation-induced tumor growth
suppression, FAK expression and phosphorylation are not altered by SP600125
treatment of β1wt /TRAMP mice. Furthermore, we have reported earlier that abrogation
of insulin-like growth factor receptor (IGF-IR) in prostate cancer cells enhances the
sensitivity to radiation. Here we further explore the β1/IGF-IR crosstalk and report
that β1 integrins promote cell proliferation partly by enhancing the expression of
IGF-IR. In conclusion, we demonstrate that β1 integrin-mediated inhibition of JNK
signaling modulates tumor growth rate upon hypofractionated radiation.

Introduction

(JNK) [3-5], a member of the MAPK family, also known
as stress-activated protein kinase [6]. Integrin regulation
of JNK signaling is complex; JNK has been shown to be
either activated by β1 or αv integrins in head and neck
[4] and in nasopharyngeal cancer [5] or suppressed by β1
integrins in prostate cancer as reported in our in vivo study
[3].

Integrin-mediated adhesion of cancer cells to the
extracellular matrix regulates the cellular response to
ionizing radiation [1-3]. Our laboratory and others have
shown that integrins regulate the response to radiation
by modulating the activity of c-Jun NH2-terminal kinase
www.impactjournals.com/oncotarget
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resistance of cancer cells [3] and unraveling the nature
of these interactions is expected to contribute not only to
understanding the mechanisms of resistance, but also in
the identification of novel therapeutic targets.
Here, we have studied β1-mediated downstream
signaling in vivo in prostate cancer resistance to
hypofractionated radiation. We report that JNK inhibition
compromises the beneficial effects of radiation therapy in
TRAMP mice carrying conditional ablation of β1 (β1pc-/- /
TRAMP), and results in a significant increase in prostate
tumor growth associated with increased FAK expression
and activity in these tumors.

While recent advances in radiotherapy have
enabled precise targeting of tumor tissue, recurrence
after radiotherapy, however, remains a concern. Many
factors may lead to the failure of radiotherapy and to
recurrence (Reviewed in [7]) including enhanced DNA
repair, activation of tumor cell survival pathways,
and inhibition of programmed cell death as well as the
presence of a subpopulation of cancer stem cells that
are inherently resistant to radiation (Reviewed in [8]).
The conventional external beam radiation therapy used
in the clinic ranges from 75.6 to 81.0 Gy of radiation
divided into 1.8- to 2.0 Gy fractions, and is carried out
daily between 7 and 9 weeks (Reviewed in [9]). Recently,
moderate (<35 fractions) and extreme (<5 fractions)
hypofractionated radiation therapy has been reported to
yield more favorable results than conventional regimens
(2 Gy/fraction), both in terms of biochemical response
and toxicity [10]. However, there is no consensus in
the scientific community whether hypofractionated
radiation significantly reduces biochemical and/or
clinical disease failure [11]. Thus, in the current study,
we have investigated the effect of hypofractionated high
dose radiation administered at shorter intervals (mice
are irradiated with a total dose of 50 Gy, carried out in
fractionated doses of 10 Gy, consecutively for 5 days).
This simulates the approach proposed for clinical use in an
effort to alleviate patient inconvenience and reduce health
care costs (Reviewed in [9]). An improved understanding
of the mechanisms involved in radiation-induced tumor
regression may ultimately provide novel strategies of
intervention in the treatment of human malignancies.
Using this hypofractionated radiation approach, we
have tested the effect of a JNK inhibitor SP600125 (SP)
on radiation response in wild type (β1wt /TRAMP) mice
as well as in mice carrying a conditional ablation of β1
integrins in the prostatic epithelium (β1pc-/- /TRAMP).
SP is a reversible ATP-competitive inhibitor of JNK that
blocks all three JNK isoforms with similar potency [12].
Its specificity is attributed to the fact that it effectively
occupies the hydrophobic pocket of the ATP binding site
in JNK1 and variations of crucial hydrophobic residues
in other MAP kinases make JNK a selective target [13].
SP has been reported to be a selective JNK inhibitor [14]
and its effectiveness against JNK in vivo has been widely
reported [15-18].
In the present study, we demonstrate that the
effects of JNK inhibition are contingent upon β1
integrin expression. We studied the signaling interface
between β1 integrins and the type-1 insulin-like growth
factor receptor (IGF-IR), a trans-membrane tyrosinekinase receptor, known to play an essential role in the
development and progression of cancer by regulating cell
proliferation, differentiation, apoptosis and metastasis
[19]. Like β1 integrins, IGF-IR signaling has been
reported to mediate resistance to radiotherapy [20, 21].
Together, these receptors play a concerted role in radiowww.impactjournals.com/oncotarget

Results
JNK inhibition in β1pc-/- TRAMP mice irradiated
in the lower pelvis leads to prostate cancer
progression
We have previously demonstrated that conditional
ablation of β1 integrins significantly improves survival
and delays prostate cancer progression in response to
lower pelvis irradiation in TRAMP mice [3]. To assess
the importance of JNK activation in response to radiation,
20 week-old β1pc-/- /TRAMP mice were treated with
hypofractionated radiation regimen that consisted of
10 Gy fractions for 5 consecutive days (total 50 Gy).
In conjunction with radiation treatment, intraperitoneal
(IP) injections of SP and PPCES (PP) were administered
three times/week and were continued for 9 additional
weeks followed by euthanasia at 35 weeks of age. This
irradiation strategy led to effective tumor suppression
in β1pc-/- /TRAMP mice. JNK inhibition in these mice
markedly compromises the effect of radiation and results
in increased tumor load at the end of the treatment
period. Histopathological analysis of prostate tissues
from irradiated β1pc-/- /TRAMP mice treated with SP
consistently reveals aggressive pathological characteristics
when compared to controls injected with PP which show
in situ carcinoma characterized by marked papillary and
cribriform epithelial proliferation with acinar expansion
(Figure 1A, left panels). High magnification images of
prostate tissues from SP-treated mice (Figure 1A, right
panel) specifically reveal invasive carcinoma composed
of anaplastic epithelioid cells growing in sheets and
nests. Individual cells show marked cytologic dysplasia
and areas of tissue necrosis within the expanded acini.
Analysis of total tumor mass in irradiated mice injected
with either PP (n = 13) or SP (n = 17) indicates that SP
treatment significantly increases tumor mass in β1pc//TRAMP mice, P < 0.0001 (Figure 1B). These results
suggest that the therapeutic effect of β1 abrogation in
response to irradiation is offset by JNK inhibition.

52619

Oncotarget

Figure 1: JNK inhibition counteracts the effect of irradiation and supports aggressive prostate growth in β1pc-/- TRAMP
mice. A. Histopathological analysis after Hematoxylin and Eosin (H&E) staining of prostate tissue from irradiated β1pc-/- /TRAMP mice.

At the age of 20 weeks, mice were subjected to IP injections of vehicle PPCES or inhibitor SP600125, administered 3 times/week for
10 weeks. Two hours after the first IP injection with either PPCES or SP600125, the lower pelvises of the mice were irradiated with a
hypofractionated radiation regimen that consisted of 10 Gy fractions (total dose 50 Gy) administered for 5 consecutive days. Mice were
euthanized at 35 weeks of age and prostate tissues were analyzed for tumor progression. Representative H&E images of tissues from control
or treated mice are shown (left panels). Scale bar 100 µm. The right panel shows representative H&E high magnification images of prostate
tumors from irradiated and SP600125-treated β1pc-/- /TRAMP mice depicting aggressive histopathology. Scale bar 50 µm. B. The tumor
mass distribution in irradiated β1pc-/- TRAMP mice injected with PPCES vehicle or SP600125-treated is shown. Median tumor weight with
interquartile range and individual data points are plotted. PPCES group n = 13 mice, SP600125 group n = 17 mice. A statistically significant
increase in tumor mass is found in the SP600125-treated cohort as compared to the cohort injected with PPCES. P < 0.0001 (WilcoxonMann-Whitney two-sided test).
www.impactjournals.com/oncotarget
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JNK inhibition in β1wt /TRAMP mice does
not interfere with radiation-induced tumor
suppression

radiation, we evaluated FAK expression and activity
profiles in our model system. Prostate tissues from
irradiated and SP- treated β1pc-/- /TRAMP mice were
analyzed for the expression and phosphorylation of
FAK. Our results demonstrate that JNK inhibition by SP
selectively leads to the up-regulation of FAK expression
and phosphorylation (Figure 4A). No changes in AKT
phosphorylation, however, are observed in these tissues
(Figure 4B). Consistent with FAK phosphorylation, we
also observe induction of tyrosine kinase Src expression
and phosphorylation upon JNK inhibition in tissues from
β1pc-/- /TRAMP mice (data not shown). In order to study
the histological localization of FAK, prostate tissues
from SP-treated β1pc-/- /TRAMP mice were analyzed for

Since we have previously demonstrated that β1
integrins suppress radiation-induced JNK activation [3],
the JNK inhibitor was not expected to elicit any changes
upon prostate irradiation in mice expressing wild type β1
(β1wt /TRAMP). To test whether JNK inhibition influences
radiation resistance in β1wt /TRAMP prostate, we carried
out irradiation and PP or SP injections in β1wt /TRAMP
mice as described above in Figure 1. Histopathological
analysis of prostate tissues from irradiated β1wt /TRAMP
mice injected with either PP or SP does not show any
tumor growth (Figure 2). Prostate tissues from SP-treated
β1wt mice show marked papillary and cribriform epithelial
hyperplasia with high-grade dysplasia (Figure 2A, right
panel). In some glands, the changes are equivalent to
in situ carcinoma; however, invasive carcinoma is not
observed in this group. The prostatic tissues from the PP
group show a spectrum of phenotypes including papillary
hyperplasia with mild atypia, papillary and cribriform
hyperplasia with high-grade dysplasia and combined
epithelial and stromal hyperplasia with minimal cytologic
atypia (Figure 2A, left panel). The differences in tumor
mass between PP (n = 15) and SP (n = 14) cohorts are not
significant, P = 0.41 (Figure 2B). These data imply that
JNK inhibition does not modify the radiation response in
β1wt tumors.
Collectively, these data show that JNK inhibition
counteracts the effect of radiation therapy in the absence of
β1 integrins and accelerates tumor growth and progression
as indicated in our schematic drawing in Figure 3A. This
is consistent with our earlier findings that JNK activation
is suppressed by β1 integrins in prostate cancer cells
[3] and with our new observation that exogenous JNK
inhibition does not affect tumor growth in β1wt mice. To
confirm SP-mediated JNK suppression in vivo, prostate
tissues isolated from irradiated controls (PP cohort) and
irradiated plus SP-treated β1pc-/- /TRAMP cohort were
evaluated for JNK function. Our results demonstrate that
SP significantly blocks the phosphorylation of JNK in
prostate tissues (Figure 3B).

JNK inhibition in vivo up-regulates the expression
and activation of FAK in irradiated β1pc-/- prostate
tumors

Figure 2: JNK inhibition in β1wt /TRAMP mice does
not offset the effect of radiation on tumor growth.

A. Histopathological analysis of irradiated tumors from β1wt /
TRAMP mice treated as described in Figure 1. Representative
H&E images of tissues from control or treated mice are shown.
Scale bar 100 µm. B. The tumor mass distribution in lower
pelvis-irradiated β1wt /TRAMP mice injected with PPCES or
SP600125 is shown. Median tumor weight and individual data
points are plotted. PPCES group n = 15 mice, SP600125 group n
= 14 mice. No statistically significant differences in tumor mass
are found between SP and vehicle treated β1wt /TRAMP cohorts.
P = 0.4094 (Wilcoxon-Mann-Whitney two-sided test).

FAK is known to support tumor growth and
metastasis [22], and in TRAMP mice reportedly
contributes to the development of neuroendocrine
carcinoma [23]. Consistent with its role in aggressive
forms of the disease, FAK signaling has been associated
with radiation resistance [24]. To investigate if β1
integrins modulate FAK signaling in the presence of
www.impactjournals.com/oncotarget
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Table 1: Expression profile and localization of FAK in prostate tissues from irradiated and/or SP-treated β1pc-/- /
TRAMP mice.
FAK intensity
FAK Positive
Mouse
JNK
inhibitor
Histopathology
Fields
Number
[Percentage]
Nuclear Cytoplasmic
1

+

Invasive carcinoma

3

-

100%

2

+

Aggressive high grade tumor, neuroendocrine 3
phenotype

-

100%

3

+

High grade tumor, carcinoma in situ

3

-

100%

4

+

High grade tumor

3

-

100%

5

+

Carcinoma in situ and high grade PIN

3

-

100%

6

+

High grade tumor

3

1

100%

7

+

High grade tumor

3

3

100%

8

+

Aggressive high grade tumor, high grade PIN, 2-3
invasive carcinoma, unusual papillary cells

2-3

90%

9

+

High grade aggressive tumor

3

3

80%

10

+

High grade tumor

2-3

2-3

80%

11

_

Carcinoma in situ, benign, PIN

1-2

1-2

100%

12

_

Well contained high grade PIN

1-2

1-2

90%

13

_

Carcinoma in situ, high grade PIN

1-2

1-2

80%

14

_

Benign, atypical to well defined PIN

1

1

70%

15

_

PIN, tumor plus dysplasia

1

1

60%

16

_

No tumor, abscess

1

-

50%

17

_

Carcinoma in situ, locally invasive, high grade 2
tumor

1

40%

18

_

Focal high grade PIN, carcinoma in situ, 1-2
papillary hyperplasia

1-2

40%

19

_

Normal glandular morphology

1

1

30%

20

_

Typical hyperplasia, no tumor

1

1

20%

At the age of 20 weeks, β1pc-/- /TRAMP mice were subjected to IP injections of vehicle PP (-) or inhibitor SP (+), administered
3 times/week for 10 weeks. Two hours after the first IP injection with either PP or SP, the lower pelvises of the mice were
irradiated with a hypofractionated radiation regimen that consisted of 10 Gy fractions (total dose 50 Gy) administered for
5 consecutive days. Mice were euthanized at 35 weeks of age and paraffin-embedded formalin-fixed prostate tissues were
analyzed for FAK expression patterns. Histological features of 10 PP and 10 SP tissues are shown. “Percentage positive areas”
at x40 optical magnification represents the number of cytoplasmic and/or nuclear FAK-positive regions over ten independent
areas in each specimen analyzed. An optical region of a sample that showed more than 50% of cells with positive FAK staining
was scored as FAK positive; FAK expression was scored using a 1-3 arbitrary scale in the FAK intensity column. -, indicates
undetectable levels.
www.impactjournals.com/oncotarget
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FAK expression patterns by immunohistochemistry. Ten
specimens in the PP and SP cohorts were studied for FAK
intensity and scored. Our data indicate that SP-treated
specimens show relatively higher FAK intensity and
enhanced nuclear localization in comparison to the PPcontrol cohort (Table 1 and Figure 5). These data highlight
the role of β1 and JNK signaling in FAK regulation and
strongly suggest a role for FAK in β1-dependent radiation
resistance of prostate cancer.

suppressing JNK1 activation in β1wt /TRAMP mice,
JNK inhibition in β1wt /TRAMP prostate tissues does not
enhance FAK signaling (Figure 6A); we also observe that
JNK inhibition in β1wt /TRAMP prostate tissues does not
enhance AKT signaling. Conversely, our results indicate
that JNK-inhibition dependent FAK up-regulation in
prostate tumors selectively occurs in the absence of
β1 integrins. We also investigated the expression of a
neuroendocrine marker, chromogranin, in β1pc-/- and β1wt
/TRAMP prostate tissues. Chromogranin expression is
detected in both β1pc-/- and β1wt tissues regardless of JNK
inhibition implying that β1, JNK or FAK signaling does
not influence chromogranin expression in our model
(Figure 6B).

JNK inhibition in vivo fails to enhance FAK/AKT
signaling upon irradiation in β1wt /TRAMP mice
Since JNK inhibition leads to the induction of FAK
signaling in β1pc-/- /TRAMP prostate tumors, we assessed
the FAK profile in β1wt /TRAMP prostate tissues. β1
integrins are known to regulate FAK signaling [4] and we
have previously demonstrated that β1 integrins suppress
radiation-induced JNK signaling in prostate cancer
[3]. Consistent with a dominant role of β1 integrins in

β1 integrins regulate IGF-IR expression to
enhance prostate cancer cell proliferation
We have previously reported that β1 integrin
expression is regulated by IGF-IR, a receptor known

Figure 4: Tumor growth upon irradiation and JNK
inhibition in β1pc-/-/TRAMP mice is associated with
enhanced FAK signaling. A. Induction of FAK expression

Figure 3: JNK signaling is crucial for radiationdependent tumor suppression in the absence of β1
integrins. A. Schematic representation showing that the

and phosphorylation in prostate tumors from β1pc-/- /TRAMP
mice. Immunoblot analysis of prostate tissues from β1pc-/- /
TRAMP mice treated as described in Figure 1. Prostate tissues
were snap frozen. Tissues were homogenized and lysates
analyzed by SDS-PAGE using Abs against FAKpY397 and total
FAK. ERK1/2 was used as a loading control. B. Immunoblotting
analysis of prostate tissues from β1pc-/- /TRAMP mice showing
AKTpS473 and total AKT in prostate tissues as described above in
Figure 4A. ERK1/2 was used as a loading control.

effect of radiation is offset by JNK inhibition in β1pc-/-/TRAMP
mice (upper panel). In contrast, the effect of radiation persists
in SP600125-treated β1wt /TRAMP mice (lower panel). B.
Immunoblot analysis shows the total and JNKpT183, pY185 levels in
irradiated prostate tissues of β1pc-/- / TRAMP mice treated as in
Figure 1.
www.impactjournals.com/oncotarget
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Figure 5: Irradiation coupled with JNK inhibition in β1pc-/- /TRAMP mice leads to increased levels of nuclear FAK in
tumor cells. FAK expression profile in paraffin-embedded tissue sections from irradiated and SP600125-treated β1pc-/- /TRAMP mice are
shown. Ten specimens in control PPCES and SP600125-treated cohorts were analyzed. Representative expression profiles are shown here.
Scale bar 50 µm.

www.impactjournals.com/oncotarget
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to promote resistance to radiation, and that abrogation
of IGF-IR in prostate cancer cells leads to the loss of
β1 integrins by proteasomal degradation [25]. Here we
investigate whether β1 integrins affect IGF-IR expression.
LNCaP cells were transiently transfected with β1-pcDNA
together with control or IGF-IR siRNA to evaluate the
expression of IGF-IR. Our results demonstrate that overexpression of β1 leads to the up-regulation of IGF-IR
(Figure 7A). However, IGF-IR down-regulation eliminates

exogenous increase in β1 protein levels suggesting that
the stability of β1 is dependent on IGF-IR, reinforcing our
previous observation that in the absence of IGF-IR, β1
is rapidly metabolized through proteasomal degradation.
Both IGF-IR and β1 receptors seem to co-exist in a
functional complex and stabilize each other’s expression in
cancer cells. As shown in Figure 7B, exogenous induction
of β1 significantly promotes cancer cell proliferation.
Concurrent IGF-IR down-regulation reduces β1 levels

Figure 6: FAK/AKT signaling is not altered upon lower
pelvis irradiation and JNK inhibition in β1wt /TRAMP
mice. A. Immunoblot analysis of prostate tissues from β1wt /

TRAMP mice treated as described in Figure 1. Frozen tissues
were homogenized and lysates analyzed by SDS-PAGE using
antibodies against total FAK, FAKpY397, total AKT and AKTpS473.
ERK1/2 was used as a loading control. B. Neuroendocrine
differentiation in response to irradiation and JNK inhibition in
either β1pc-/- /TRAMP or β1wt /TRAMP prostate tissues. Number
of mice analyzed: PPCES group β1pc-/- /TRAMP, n = 5; SP600125
group β1pc-/- /TRAMP, n = 3; PPCES group β1wt /TRAMP, n = 3
and SP600125 group β1wt /TRAMP, n = 3. Representative images
reflecting the expression profile of chromogranin in β1pc-/- or β1wt
TRAMP mice. Prostate tissues from β1pc-/- or β1wt /TRAMP mice
treated as in Figure 1A above were fixed; sections were stained
with a chromogranin Ab and processed for immunofluorescence.
Counterstaining was done with DAPI not shown and expression
profiles were studied by confocal microscopy. Scale bar 100 µm.
www.impactjournals.com/oncotarget

Figure 7: β1 integrins promote cancer cell proliferation
by regulating the expression of IGF-IR. A. Exogenous

β1 induction leads to the up-regulation of IGF-IR expression.
LNCaP cells were transiently transfected with either pBJ1 or
β1-pBJ1 constructs, together with control or IGF-IR siRNA;
48 hours later, cell lysates were analyzed by immunoblotting
analysis for expression of the β1 integrin subunit and IGF-IR.
AKT was used as a loading control. B. Exogenous β1 induction
enhances cancer cell proliferation, which is blocked by IGFIR knockdown. LNCaP cells transfected as in Figure 7A were
replated in equal numbers in culture dishes and allowed to grow
for either 3 or 6 days followed by live cell counting. Each assay
was performed in triplicate and asterisk signs represent statistical
significance.
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and thus significantly stalls cell proliferation suggesting
that β1 functions are intrinsically dependent on IGFIR expression in prostate cancer cells. Thus, it could be
speculated that both IGF-IR and β1 receptors concertedly
modulate JNK signaling in response to radiation.

tyrosine 397 (FAKpY397) exposes a site for Src, which leads
to Src-dependent phosphorylation of FAK at tyrosines
576 (FAKpY576) and 577 (FAKpY577) leading to maximal
adhesion-induced FAK activation [32]. FAK expression
has been reported to be enhanced in all stages of prostate
tumorigenesis, to regulate anti-tumor immunity and
integrin-dependent radioresistance [33-36]. Recently,
nuclear FAK was reported to regulate immunomodulatory
functions and inhibit anti-tumor immunity in cancerous
squamous epithelial cells by regulating chemokine/
cytokine and ligand receptor networks [36], which is
consistent with our results. FAK activity has further been
implicated in DNA damage induced NF-kB activation
and production of cytokines from endothelial cells
leading to chemoresistance [37]. Similarly, β1 integrindependent FAK signaling was reported to elicit faster cell
attachment rates and reduced adhesion strength in taxolresistant ovarian cancer cells [38]. The authors report that
adhesion strength is dependent on FAK. Besides, faster
attachment rates and reduced adhesion strength, in these
cells, correlate with increased β1 integrin expression
and decreased focal adhesion formation, respectively. In
addition, drug-tolerant microenvironments are known
to be correlated with high β1 integrin/FAK signaling
in melanoma cells [39]. Our data indicating high FAK
expression and phosphorylation associated with tumor
progression upon radiation, are consistent with these
studies and collectively highlight a central role of FAK in
therapeutic resistance.
Activation of AKT has been reported earlier as an
important predictor of the probability of PSA failure and a
marker of clinically aggressive prostate cancer [40]. There
is a significant interest in developing effective strategies
to target this pathway [41]. In our studies, however, AKT
activation in irradiated prostate tissues does not change
upon JNK inhibition ruling out a significant functional
contribution of JNK-dependent AKT activation in
prostate cancer development in SP-treated β1pc-/- TRAMP
mice. Finally, although sustained FAK expression and
activity have been reported to be essential for androgenindependent formation of neuroendocrine carcinoma
[23], we observe significant chromogranin expression in
TRAMP tissues that is not altered by either JNK inhibition
or β1 abrogation.
Furthermore, our earlier report showed that
abrogation of IGF-IR in prostate cancer cells enhances the
sensitivity to radiation in a clonogenic assay [25]. Here
we show that β1 integrins promote cell proliferation partly
by enhancing the expression of IGF-IR underscoring
the importance of β1/IGF-IR functional synergy. Using
in vitro model systems of prostate cancer we have
demonstrated a functional crosstalk between β1 integrins
and IGF-IR and shown that these two vital receptors
regulate each others’ expression [25]. In the present
report, we further demonstrate that exogenous β1 integrins

Discussion
Using a novel hypofractionated radiation schedule
that effectively blocks prostate tumor growth in TRAMP
mice, we show that blocking JNK signaling using a JNK1,
2 and 3 inhibitor (SP600125), counteracts the effects of
therapeutic radiation and leads to tumor growth and
progression, in a β1 integrin-dependent manner.
Here we have tested a hypofractionated radiation
scheme where a 50 Gy total dose of radiation was
administered in 10 Gy fractions for 5 consecutive days,
to approximate the hypofractionated approach in patients.
This radiation schedule effectively suppresses tumor
growth in β1wt mice and also in β1pc-/- mice which carry
a conditional ablation of β1 integrins in the prostatic
epithelium. However, inhibition of JNK phosphorylation
negates the therapeutic effect of hypofractionated radiation
in β1pc-/- /TRAMP but not β1wt /TRAMP mice. This is
consistent with the notion that β1 integrin-dependent
signaling determines the functional role of JNK as it
relates to radiation response of the prostate epithelium.
Our study delineates a JNK-mediated signaling
pathway, which modulates tumor growth upon irradiation
in a differential manner dependent on β1 expression.
It is widely accepted that ionizing radiation activates
multiple signal transduction pathways, including the
JNK/SAPK cascade, which transduce death signals from
the cell membrane to the nucleus. Since β1 integrins
suppress JNK activation induced by radiation [3], SP
treatment, as expected, did not affect radiation-induced
tumor suppression in β1wt mice. Our results are in contrast
with a previous report where inhibition of β1 integrins
in head and neck carcinoma cells was reported to be
associated with down-regulation of JNK signaling leading
to radiosensitization [4]. However, there is substantial
evidence demonstrating a pro-apoptotic role of JNK in
response to radiation [26-29], which is consistent with our
results. Although integrin interaction with the cytoskeleton
is likely to mediate JNK activation, the association of β1
with the cytoskeletal protein, filamin A [30] is not likely
to explain our results since filamin A binds stress signaling
kinases MKK4 and MKK7 and is known to enhance JNK
activation [31] whereas β1 integrins suppress radiationdependent JNK signaling.
A unique feature of irradiated and SP-treated β1pc-/tumors is the up-regulation of FAK expression and autophosphorylation which is not observed in β1pc-/- tissues
from mice with functional JNK signaling or in β1wt tissues
where JNK is inhibited. FAK auto-phosphorylation at

www.impactjournals.com/oncotarget
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SP injection and hypofractionated irradiation

up-regulate IGF-IR expression leading to enhanced
cell proliferation. This is consistent with our previous
findings where abrogation of IGF-IR led to reduced
β1 levels via proteasomal degradation and enhanced
radiation sensitivity of prostate cancer cells [3, 25]. The
identification of aberrant signaling pathways broaden the
current concept of radiation sensitivity in exploring multitargeting molecular agents and aid in the development of
novel therapeutic approaches.
In summary, we demonstrate that inhibition of
JNK reactivates the growth of irradiated tumors, in a
differential manner that depends on β1 integrins, and
promotes FAK expression and activity. These findings
have implications for the future design of combination
therapies encompassing ionizing radiation and signal
transduction modifiers.

SP was suspended in PP mixture comprising of 30%
PEG-400, 20% polypropylene glycol, 15% cremophor,
5% ethanol and 30% saline [12]. At the age of 20 weeks,
β1pc-/- /TRAMP and β1wt /TRAMP mice were subjected to
IP injections of vehicle PP (150µl) or inhibitor SP (30mg/
kg), administered 3 times / week for 10 weeks. Two hours
after the first IP injection with either PP or SP, the lower
pelvis of the mice was irradiated with 10 Gy radiation as a
part of hypofractionated radiation regimen that consisted
of 10 Gy fractions (total dose 50 Gy) administered for
5 consecutive days. Animals were anesthetized with
Ketamine-Xylazine-Acepromazine mixture (0.125
ml/100g of body weight),(Ketamine, 80 mg/ml; Xylazine
5 mg/ml; Acepromazine, 1.6 mg/ml) providing 25-30
minutes sedation, prior to being placed in malleable lead
shielding. The shield ensures that upper body including
upper gastrointestinal tract is protected. Lower pelvises
of mice were irradiated using a PanTak 310keV X-ray
machine at 0.25mm Cu plus 1mm Al added filtration,
at 125 cGy/min. Mice were euthanized at the age of 35
weeks for studying tumor progression. Prostate isolation
was performed using a dissection stereomicroscope
SZX10 (Olympus). Prostate tissues were weighed and
fixed for histopathologic analysis. A small amount of
tissue was frozen for immunoblotting analysis. Lungs,
liver and lymph nodes were fixed for studying metastasis.

Materials and methods
Reagents and antibodies
SP600125 (SP) was purchased from LC
Laboratories. Murine monoclonal (m) antibodies
(Abs) against the following antigens were used: human
β1, TS2/16 (ATCC); β1, clone-18; JNK1/JNK2 (BD
Pharmingen); c-Src (Cell Signaling). Rabbit polyclonal
Abs against the following antigens were used: IGF-IR
(IGF-IR-β sc713); AKT; FAK; ERK1/2 (Santa Cruz);
chromogranin (Invitrogen); FAKpY397, SrcpY416, JNKpT183,
pY185
, AKTpS473 and AKT (Cell Signaling). Non-immune
rabbit IgG was purchased from Pierce. Alexa Fluor 488
goat anti-rabbit IgG was purchased from Invitrogen.

Immunohistochemistry (IHC)

LNCaP prostate cancer cells were purchased from
ATCC and authenticated by the supplier. Cells were grown
at 37°C and 5% CO2 in RPMI-1640 supplemented with
5% FBS and 1%, each of sodium pyruvate, HEPES and
non-essential amino acids.

IHC analysis was carried out as reported earlier [3].
Lungs, liver and lymph nodes from mice were processed
in the same manner and stained with H&E for studying
metastasis. Histological analysis of prostate and metastases
was performed by Dr. Peter McCue. Total FAK levels
were analyzed in paraffin-embedded formalin-fixed tumor
sections of β1pc-/- /TRAMP mice by IHC as reported earlier
for other molecules [42], with the exception of using
biotin-streptavidin-amplified peroxidase immunodetection
system with DAB kit (Invitrogen).

Mice

Immunofluorescence and confocal microscopy

TRAMP mice carrying conditional ablation of β1
(β1 /TRAMP) and those expressing wild type β1 (β1wt
/TRAMP) were generated as described earlier [3]. Care
of animals was in compliance with standards established
by the office of laboratory animal welfare, Department
of Health and Human Services at NIH. Experimental
protocols were approved by the Institutional Animal Care
and Use Committee, Thomas Jefferson University.

Immunofluorescence was carried out as described
earlier [43]. Staining with an Ab to chromogranin was
performed by incubation of tissue samples with primary
Abs (1:100) for 1 hour at RT, followed by incubation with
Alexa Fluor 488 goat rabbit IgG (1:250) for 20 minutes
at RT.

Cell lines

pc-/-
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Transient transfection

Department specifically disclaims responsibility for
any analyses, interpretations or conclusions; the Sidney
Kimmel Cancer Center Bioimaging and Histology Core
Facilities were supported by the NCI, National Institutes
of Health, under Award P30CA056036.

Transfection of cells with siRNA oligonucleotides
(Thermo Scientific) was performed as previously described
[44]. To -regulate IGF-IR, the sequences of sense strands
of duplex siRNAs used are as follows: IGF-IR-siRNA:
5’-CGACUAUCAGCAGCUGAAGUUdTdT-3’; control
IGF-IR-siRNA: 5’-GAAGUCGACGACUAUCAGCU
UdTdT-3’ [25].
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